Business Wire

J-HOTATE-ASSOCIATION

15.4.2024 13:01:34 CEST | Business Wire | Press release

Share
J-HOTATE Association Exhibits at Seafood Expo Global in Spain to appeal premium and fresh Japanese scallops

Japan Scallop Export Promotion Association (“J-HOTATE Association”), which aims to expand the export of Japanese scallops, will be presenting the Japanese scallops to European markets at the Seafood Expo Global, which will be held in Barcelona, Spain, from April 23rd to April 25th, 2024.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240415920416/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Japanese Scallop - A Sustainable Gastronomic Delight (Photo: Business Wire)

Japanese scallops (we say HOTATE [Hoh-Tah-Teh]) are highly accredited for their flavor, size, and quality. Fresh scallops can be enjoyed year-round under environmentally friendly farming/harvesting methods and the advanced technology to maintain freshness—both of which are unique to Japan. Especially in Hokkaido, Aomori, Iwate, and Miyagi where scallops are produced, local ocean currents provide highly rich nutrients, boasting one of the world’s largest landings of scallops.

Scallops are also known as a healthy seafood. They are rich in nutrients such as vitamin B1, which is effective in alleviating fatigue and improving concentration, and taurine, which is known to improve heart and liver function and help to prevent diabetes. Furthermore, scallops are high in protein and low in calories, making them fit to be a superfood.

Japan is unique to other parts of the world in that the proximity of fishing grounds and ports allows for scallops to be processed and distributed immediately after they are caught, and it has become a common custom in Japan for scallops to be eaten raw. Today, scallops are rapidly frozen right after landing, allowing overseas distribution while maintaining quality.

Exports of Japanese scallop products from Japan to other countries reached a record high of 94.5 billion JPY (approx. 128,000 tons in weight) in 2022, surpassing double its value (over 1.6 times in weight) of that of 2020, when markets stalled due to COVID-19.

Export Data of Japanese Scallops (worldwide)

(Units: tons/millions JPY/kg)

2020

2021

2022

Weight

Amount

PPU

Weight

Amount

PPU

Weight

Amount

PPU

Raw

13,990

5,090

364

19,597

8,173

417

16,356

9,512

582

Dried

1,167

7,154

6,128

994

5,967

6,001

454

3,914

8,628

Frozen

63,556

26,216

412

96,392

55,877

580

111,392

81,099

728

Total

78,713

38,460

489

116,983

70,018

599

128,203

94,526

737

Source: J-HOTATE Association

The association has participated in the Seafood Expo in Boston and Singapore and received positive reactions from local firms of North America and Asian countries interested in connecting with Japanese scallop suppliers.

Our goals with the first exhibition in Europe are to increase the export of Japanese scallops and promote the traditional Japanese "eating raw" culture to taste the fullness of scallops' rich nutritional value. The booth will include a business meeting space, introduction of Japanese scallop products and production areas, as well as showing samples of scallops at regular and frozen temperatures, and providing tasting samples of scallops, shipped straight from Japan in Sushi/Sashimi and fried styles.

[Exhibit Information]
Event: Seafood Expo Global (https://www.seafoodexpo.com/global/)
Booth Number: 1F701 (Hall 1)
Date: April 23–April 25, 2024
Venue: FIRA BARCELONA GRAN VIA VENUE

About Japan Scallop Export Promotion Association (“J-HOTATE Association”)

The Japan Scallop Export Promotion Association (J-HOTATE Association) was incorporated in October 2023, with the aim of expanding exports of Japanese scallop products with high quality and healthy flavours through sustainable cultivation. The J-HOTATE Association is currently composed of seventy-four members, including producers (fishery cooperative associations), processors and fisheries-related distributors of Japan and traders. https://j-hotate.com/

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240415920416/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release

Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to

Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release

About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,

AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release

Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break

Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release

Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti

Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release

Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye